Liposomes and liposome-like nanoparticles:From anti-fungal infection to the COVID-19 pandemic treatment  

作　　者：Yonglong He Wanting Zhang Qingqing Xiao Lifang Fan Dechun Huang Wei Chen Wei He 

机构地区：[1]School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China [2]Jiangsu Aosaikang Pharmaceutical Co.,Ltd.,Nanjing 211112,China [3]School of Engineering,China Pharmaceutical University,Nanjing 210009,China [4]Shanghai Skin Disease Hospital,Tongji University School of Medicine,Shanghai 200443,China

出　　处：《Asian Journal of Pharmaceutical Sciences》2022年第6期817-837,共21页亚洲药物制剂科学（英文）

基　　金：supported by the National Natural Science Foundation of China(Nos.81872823 and 82073782);the Shanghai Science and Technology Committee(No.19430741500);the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine(zdsys-202103)。

摘　　要：The liposome is the first nanomedicine transformed into the market and applied to human patients.Since then,such phospholipid bilayer vesicles have undergone technological advancements in delivering small molecular-weight compounds and biological drugs.Numerous investigations about liposome uses were conducted in different treatment fields,including anti-tumor,anti-fungal,anti-bacterial,and clinical analgesia,owing to liposome's ability to reduce drug cytotoxicity and improve the therapeutic efficacy and combinatorial delivery.In particular,two liposomal vaccines were approved in 2021 to combat COVID-19.Herein,the clinically used liposomes are reviewed by introducing various liposomal preparations in detail that are currently proceeding in the clinic or on the market.Finally,we discuss the challenges of developing liposomes and cutting-edge liposomal delivery for biological drugs and combination therapy.

关 键 词：Liposomes Drug delivery Clinical application COVID-19 pandemic 

分 类 号：R511[医药卫生—内科学]